Physician profile
Vasdev Lohano
NPI 1316906738
$6,075.22
in general payments reported to CMS, 2019-2025
32 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,792 · 2020: $191 · 2022: $443 · 2023: $2,388 · 2024: $737 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872 · Consulting Fee: $1,740 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.77 |
| Consulting Fee | $1,740.00 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,984.32 | 2019-2023 | |
| Insulet Corporation | $425.96 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $336.06 | 2019-2025 | |
| Dexcom, INC. | $268.34 | 2019-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $241.46 | 2019-2020 | |
| Amgen INC. | $219.85 | 2019-2024 | Repatha |
| Abbott Laboratories | $212.90 | 2019-2022 | |
| Medtronic, INC. | $187.94 | 2023-2024 | Minimed 780g, Azure Xt Dr Mri Surescan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.58 | 2019-2025 | Jardiance |
| Shire North American Group INC | $158.86 | 2019 | |
| Corcept Therapeutics | $149.12 | 2019 | |
| Lilly USA, LLC | $146.63 | 2019-2022 | |
| Abiomed | $145.77 | 2025 | |
| Amryt Pharma Holdings Ltd | $139.08 | 2023 | Mycapssa |
| Neurocrine Biosciences, INC. | $131.00 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Genzyme Corporation | $124.99 | 2023 | |
| Esperion Therapeutics, INC. | $124.97 | 2022 | |
| Beta Bionics, INC. | $113.98 | 2024 | Ilet Bionic Pancreas |
| Kiniksa Pharmaceuticals, Ltd. | $112.99 | 2023 | |
| Radius Health, INC. | $105.39 | 2019 | |
| Amarin Pharma, INC. | $89.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $76.41 | 2019-2020 | |
| Medtronic Minimed, INC. | $68.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $67.21 | 2019 | |
| Mannkind Corporation | $45.89 | 2025 | |
| Alexion Pharmaceuticals, INC. | $25.62 | 2019 | |
| Abbvie INC. | $23.65 | 2024 | |
| Averitas Pharma INC. | $19.20 | 2024 | Qutenza |
| Tandem Diabetes Care, INC. | $16.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.61 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasdev Lohano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.